FACS-based detection of extracellular ASC specks from NLRP3 inflammasomes in inflammatory diseases - Topping, Joanne; Lara-Reyna, Samuel; Ibbotson, Alice; Jarosz-Griffiths, Heledd; Chang, Leon; Poulter, James; Peckham, Daniel; McDermott, Michael F.; Savic, Sinisa; ImmunAID Consortium (medRxiv, 2024)
The apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) is crucial for inflammasome assembly and activation of several inflammasomes, including NLRP3. ASC aggregates are detected in human sera post pyroptotic cell death, but their inflammasome origin remains unclear. This study aimed to develop a method to detect ASC aggregates originating from NLRP3 inflammasomes. Initially, human monocytes, macrophages, and THP-1 ASC reporter cells were employed to validate the detection of ASC/NLRP3-positive events through flow cytometry. The presence of ASC/NLRP3 specks was confirmed in cell supernatants from monocytes and macrophages treated with LPS and nigericin or ATP. Flow cytometry analysis identified double-positive specks in patient sera from inflammatory conditions when compared to healthy controls. Elevated ASC/NLRP3 specks were observed in conditions such as CAPS and Schnitzler’s syndrome. We validated FACS as a reliable method for detecting ASC/NLRP3 specks in human sera, with potential diagnostic and monitoring applications in certain systemic autoinflammatory diseases.Competing Interest StatementThe authors have declared no competing interest.Funding StatementJT, MFM and SS are supported by the EU Horizon 2020 research and innovation programme (ImmunAID; grant agreement number 779295); SS is supported by a Senior Fellowship from Kennedy Trust; SC was supported by Cancer Research UK (grant number A29685). This paper presents independent research supported by the National Institute for Health Research (NIHR) Leeds Biomedical Research Centre (BRC). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social CareAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Samples were collected from adults with cystic fibrosis (CF) homozygous for F508Δ, known to exhibit elevated levels of serum ASC specks. Ethical approval for the study was granted by the Yorkshire and The Humber Research Ethics Committee (17/YH/0084). Sera from HC and patients with various systemic autoinflammatory conditions, were sourced from the ImmunAID consortium (IMMUNome project consortium for AutoInflammatory Disorders). This study was approved by the South West - Frenchay Research Ethics Committee (REC Reference: 20/SW/0022).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data that support the findings of this study are available from the corresponding author, (SS), upon reasonable request.